Market Overview

Akorn Shares Gaining On $41 Million Sale Of Branded Drugs Unit To Valeant

Related AKRX
Earnings Scheduled For February 26, 2015
Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks
Akorn, Avago Lead IBD 50 Stocks In Earnings Growth (Investor's Business Daily)

Akorn (NASDAQ: AKRX) sold its branded drug unit for $41 million and saw its shares gain nearly four percent Friday morning.

The unit, ECR Pharmaceuticals, went to Valeant Pharmaceuticals (NYSE: VRX) for a combination of $41 million cash and debt, Akorn said.

ECR was part of Akorn's $640 million acquisition of Hi-Tech Pharmacal about a year ago.

Chief Executive Raj Rai said the unit is a "solid platform" but not "a strategic fit" with Akorn's model of of focusing on niche dosage forms.

Akorn, which posted first-quarter revenue of $90.6 million, will update 2014 guidance in an earnings conference call in August.

Akorn shares traded recently at $29, up 3.45 percent.

Posted-In: News


Related Articles (AKRX + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content